Scientific Publications

July 27, 2024 / Lancet

Assessing the efficacy and tolerability of PET-guided BrECADD versus eBEACOPP in advanced-stage, classical Hodgkin lymphoma (HD21): a randomised, multicentre, parallel, open-label, phase 3 trial

P. Borchmann
J. Ferdinandus
G. Schneider
A. Moccia
R. Greil
M. Hertzberg
V. Schaub
A. Hüttmann
F. Keil
J. Dierlamm
M. Hänel
U. Novak
J. Meissner
A. Zimmermann
S. Mathas
J.M. Zijlstra
A. Fosså
A. Viardot
B. Hertenstein
S. Martin
P. Giri
S. Scholl
M.S. Topp
W. Jung
V. Vucinic
H.J. Beck
A. Kerkhoff
B. Unger
A. Rank
R. Schroers
C.M. zum Büschenfelde
M. de Wit
K. Trautmann-Grill
P. Kamper
D. Molin
S. Kreissl
H. Kaul
B. von Tresckow
S. Borchmann
K. Behringer
M. Fuchs
A. Rosenwald
W. Klapper
H.T. Eich
C. Baues
A. Zomas
M. Hallek
M. Dietlein
C. Kobe
V. Diehl

JUN mediates the senescence associated secretory phenotype and immune cell recruitment to prevent prostate cancer progression

T. Redmer
M. Raigel
C. Sternberg
R. Ziegler
C. Probst
D. Lindner
A. Aufinger
T. Limberger
K. Trachtova
P. Kodajova
S. Högler
M. Schlederer
S. Stoiber
M. Oberhuber
M. Bolis
H.A. Neubauer
S. Miranda
M. Tomberger
N.S. Harbusch
I. Garces de Los Fayos Alonso
F. Sternberg
R. Moriggl
J.P. Theurillat
B. Tichy
V. Bystry
J.L. Persson
S. Mathas
F. Aberger
B. Strobl
S. Pospisilova
O. Merkel
G. Egger
S. Lagger
L. Kenner

High-dose chemotherapy and autologous haematopoietic stem-cell transplantation in older, fit patients with primary diffuse large B-cell CNS lymphoma (MARTA): a single-arm, phase 2 trial

E. Schorb
L.K. Isbell
A. Kerkhoff
S. Mathas
F. Braulke
G. Egerer
A. Röth
S. Schliffke
P. Borchmann
U. Brunnberg
F. Kroschinsky
R. Möhle
A. Rank
D. Wellnitz
B. Kasenda
L. Pospiech
J. Wendler
F. Scherer
M. Deckert
E. Henkes
P. von Gottberg
D. Gmehlin
M. Backenstraß
A. Jensch
E. Burger-Martin
O. Grishina
H. Fricker
N. Malenica
A. Orbán
J. Duyster
G. Ihorst
J. Finke
G. Illerhaus

c-FLIP mediates resistance of Hodgkin/Reed-Sternberg cells to death receptor-induced apoptosis

S. Mathas
A. Lietz
I. Anagnostopoulos
F. Hummel
B. Wiesner
M. Janz
F. Jundt
B. Hirsch
K. Joehrens-Leder
H.P. Vornlocher
K. Bommert
H. Stein
B. Doerken

Jagged1-induced notch signaling drives proliferation of multiple myeloma cells

F. Jundt
K. Schulze-Proebsting
I. Anagnostopoulos
G. Muehlinghaus
M. Chatterjee
S. Mathas
R.C. Bargou
R. Manz
H. Stein
B. Doerken

In the presence of bone marrow stromal cells human multiple myeloma cells become independent of the IL-6/gp 130/STAT3 pathway

M. Chatterjee
D. Hoenemann
S. Lentzsch
K. Bommert
C. Sers
P. Herrmann
S. Mathas
B. Doerken
R.C. Bargou

Nuclear factor κB-dependent gene expression profiling of Hodgkins disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity

M. Hinz
P. Lemke
I. Anagnostopoulos
C. Hacker
D. Krappmann
S. Mathas
B. Doerken
M. Zenke
H. Stein
C. Scheidereit

Anti-CD20-and B-cell receptor-mediated apoptosis: Evidence for shared intracellular signaling pathways

S. Mathas
A. Rickers
K. Bommert
B. Doerken
M.Y. Mapara

Constitutive NF-kappaB maintains high expression of a characteristic gene network, including CD40, CD86, and a set of antiapoptotic genes in Hodgkin/Reed-Sternberg cells

M. Hinz
P. Loeser
S. Mathas
D. Krappmann
B. Dörken
C. Scheidereit

Inhibition of NF-κB essentially contributes to arsenic-induced apoptosis

S. Mathas
A. Lietz
M. Janz
M. Hinz
F. Jundt
C. Scheidereit
K. Bommert
B. Doerken